Home CSN news Covid-19 rapid testing at DP World Limassol’s Passenger Terminal

Covid-19 rapid testing at DP World Limassol’s Passenger Terminal

  • At least 20% of port workers and users were tested last Friday, in adherence with the latest government instructions, while tests will continue in the upcoming weeks
  • DP Worlds joins forces with UNICEF to support the global distribution of Covid-19 vaccines

DP World Limassol’s Passenger Terminal has been designated by the Ministry of Health as a central Covid-19 rapid testing location for the Limassol port community.

Tests will be carried out on Fridays, in accordance with the new measures announced by the Ministry of Health on 27 January 2021, and in coordination with Cyprus Ports Authority.

At least 20% of port workers and users were tested at the first screening of the Ministry of Health on Friday 29 January 2021 at the arrivals area of the New Passenger Terminal from 10am to 3pm. As the host of the activity, DP World Limassol took all the necessary steps to ensure the safety of all port employees who arrived at its premises to get tested.

Stressing the importance of this initiative, DP World Limassol’s CEO, Nawaf Abdulla said that “regularly testing port workers and users is imperative in order to safeguard everyone’s health and safety, as well as to ensure the smooth operation of the port, thereby making sure that the country’s supply chain remains uninterrupted”.

“At the same time”, he noted, “with a primary emphasis on the health of our employees, the safety measures and contingency plans that we have deployed since the outset of the pandemic, remain in place to ensure the smooth continuity of our operations.”

Through its new partnership with UNICEF, DP World is supporting the global distribution of COVID-19 vaccines and related immunisation supplies in low- and lower-middle-income countries. Specifically, as a leader in global end-to-end supply chain logistics, DP World will provide UNICEF with logistics solutions and supply-chain expertise, helping it procure and supply 2 billion doses of COVID-19 vaccines and auxiliary vaccination supplies on behalf of the COVAX Facility.